Documented formulations for conditions that require daily, year-on-year reliability.
Each product in this portfolio carries batch-consistency records, verified regulatory status, and specification sheets available on request. No substitutes for documented review.
Three focused areas. Consistent batch records across each.
Antihypertensives & Lipid Modulators
Glycemic Control & Thyroid Agents
Bronchodilators & Inhaled Corticosteroids
Oral tablets and extended-release capsules. Dosage forms: 5 mg, 10 mg, 20 mg. Regulatory status: FDA-approved ANDA. Batch records available.
Immediate and modified-release tablets. Dosage forms: 500 mg, 850 mg, 25 mcg, 50 mcg. Regulatory status: FDA-approved ANDA. Batch records available.
Dry-powder inhalers and oral formulations. Dosage forms: 100 mcg, 250 mcg, 4 mg. Regulatory status: FDA-approved ANDA. Batch records available.
Indicated for long-term hypertension and dyslipidemia management. Suitable for formulary substitution review.
Formulated for daily chronic use in type 2 diabetes and hypothyroidism. Narrow therapeutic index protocols applied.
Designed for persistent asthma and COPD maintenance. Device-formulation compatibility documented per lot.
Every batch held to the same release protocol.
Specification sheets document dissolution profiles, assay results, and impurity controls per batch. Procurement teams receive full lot-level traceability on request.
Dosage form selection for each product reflects chronic-use compliance data: unit-dose packaging, scored tablets where indicated, and stability testing under real-world storage conditions.
Sampling and specification sheets on request.
No online substitution for documented review. Formulary and procurement teams receive full technical packages through our partner relations channel.